Vitamin D receptor ligand therapy in chronic kidney disease

Clinical Nephrology

Volumn 70, Issue 4, 2008, Pages 271-283

  Gonzalez E A ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; VDR ligand; Vitamin D

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; ALFACALCIDOL; CALCITRIOL; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE BINDING AGENT; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; VITAMIN D RECEPTOR LIGAND;

BONE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; DIET RESTRICTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; FEEDBACK SYSTEM; GENE EXPRESSION; HORMONAL REGULATION; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; REVIEW; SECONDARY HYPERPARATHYROIDISM; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 54949087469     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp70271     Document Type: Review

References (82)

1. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease. Evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1-266.
2. Adams JS, Gacad MA. Characterization of 1 α-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exp Med. 1985; 161: 755-765.
3. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005; 68: 2823-2828.
4. Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis. 2007; 50: 59-68.
5. Balint E, Marshall CF, Sprague SM. Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro. Am J Kidney Dis. 2000; 36: 789.
6. Barbour GL, Coburn JW, Slatopolsky E, Norman AW, Horst RL. Hypercalcemia in an anephric patient with sarcoidosis: evidence for extrarenal generation of 1,25-dihydroxyvitamin D. N Engl J Med. 1981; 305: 440-443.
7. Barry JB, Leong GM, Church WB, Issa LL, Eisman JA, Gardiner EM. Interactions of SKIP/NCoA-62, TFIIB, and retinoid X receptor with vitamin D receptor helix H10 residues. J Biol Chem. 2003; 278: 8224-8228.
8. Brown AJ, Finch J, Takahashi F, Slatopolsky E. Calcemic activity of 19-Nor-1,25(OH)(2)D(2) decreases with duration of treatment. J Am Soc Nephrol. 2000; 11: 2088-2094.
9. Brown AJ, Dusso AS, Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant. 2002; 17 (Suppl 10): 10-19.
10. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000; 36: 1115-1121.
11. Coladonato JA, Ritz E. Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among end-stage renal disease patients. Adv Ren Replace Ther. 2002; 9: 193-199.
12. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41: 1-12.
13. 3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis. 2002; 40: 1283-1288.
14. Cunningham J. New vitamin D analogues for osteodystrophy in chronic kidney disease. Pediatr Nephrol. 2004; 19: 705-708.
15. Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004; 19: 1174-1181.
16. Dusso AS, Thadhani R, Slatopolsky E. Vitamin D receptor and analogs. Semin Nephrol. 2004; 24: 10-16.
17. 2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol. 1999; 10: 980-985.
18. 2 on inducing differentiation and markers of bone formation in MG-63 cells. J Am Soc Nephrol. 2001; 12: 1468-1474.
19. 2 Study Group. Nephrol Dial Transplant. 1998; 13 (Suppl 3): 68-72.
20. Fryer RM, Rakestraw PA, Nakane M, Dixon D, Banfor PN, Koch KA, Wu-Wong JR, Reinhart GA. Differential Inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol. 2007; 106: 76.
21. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest. 1993; 92: 1686-1696.
22. Gilbertson DT, Liu J, Xue JL, Louis TA, Solid CA, Ebben JP, Collins AJ. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol. 2005; 16: 3736-3741.
23. Haussler MR, Haussler CA, Jurutka PW, Thompson PD, Hsieh JC, Remus LS, Selznick SH, Whitfield GK. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol. 1997; 154 (Suppl): S57-S73.
24. Healy MD, Malluche HH, Goldstein DA, Singer FR, Massry SG. Effects of long-term therapy with calcitriol in patients with moderate renal failure. Arch Intern Med. 1980; 140: 1030-1033.
25. Holliday LS, Gluck SL, Slatopolsky E, Brown AJ. 1,25-dihydroxy-19-Nor-vitamin D(2), a vitamin D analog with reduced bone resorbing activity in vitro. J Am Soc Nephrol. 2000; 11: 1857-1864.
26. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med. 1995; 333: 166-174.
27. Hsu CH, Patel S, Buchsbaum BL. Calcitriol metabolism in patients with chronic renal failure. Am J Kidney Dis. 1991; 17: 185-190.
28. Hudson JQ. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies. Ann Pharmacother. 2006; 40: 1584-1593.
29. 3 receptors in parathyroid glands. Preliminary characterization of cytoplasmic and nuclear binding components. J Biol Chem. 1978; 253: 1065-1073.
30. Issa LL, Leong GM Sutherland RL, Eisman JA. Vitamin D analogue-specific recruitment of vitamin D receptor coactivators. J Bone Miner Res. 2002; 17: 879-890.
31. Jakoby MGT, Semenkovich CF. The role of osteoprogenitors in vascular calcification. Curr Opin Nephrol Hypertens. 2000; 9: 11-15.
32. Joist HE, Ahya SN, Giles K, Norwood K, Slatopolsky E, Coyne DW. Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. Clin Nephrol. 2006; 65: 335-341.
33. Jones G, Strugnell SA, DeLuca HF. Current understanding of the molecular actions of vitamin D. Physiol Rev. 1998; 78: 1193-1231.
34. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000; 87: E10-E17.
35. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006; 70: 771-780.
36. Kausz AT, Khan SS, Abichandani R, Kazmi WH, Obrador GT, Ruthazer R, Pereira BJ. Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol. 2001; 12: 1501-1507.
37. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994; 46: 855-861.
38. LeLorier J, Gregoire G, Benhaddad A, Lopierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med. 1997; 337: 536-542.
39. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int. 2005; 68: 1973-1981.
40. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007; 71: 31-38.
41. Lindberg J, Martin KJ, Gonzalez EA, Acchiardo SR, Valdin JR, Soltanek C. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol. 2001; 56: 315-323.
42. 2. Am J Kidney Dis. 1998; 32: S48-S54.
43. Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis. 2001; 38: S45-S50.
44. London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Metivier F. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol. 2007; 18: 613-620.
45. 2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol. 1998; 9: 1427-1432.
46. Martin KJ et al. Poster. J Am Soc Nephrol. 2006 17: Poster.
47. Maxwell DR, Benjamin DM, Donahay SL, Allen MK, Hamburger RJ, Luft FC. Calcitriol in dialysis patients. Clin Pharmacol Ther. 1978; 23 : 515-519.
48. McClellan WM, Knight DF, Karp H, Brown WW. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines. Am J Kidney Dis. 1997; 29: 368-375.
49. Migliori M, Giovannini L, Panichi V, Filippi C, Taccola D, Origlia N, Mannari C, Camussi G. Treatment with 1,25-dihydroxyvitamin D3 preserves glomerular slit diaphragm-associated protein expression in experimental glomerulonephritis. Int J Immunopathol Pharmacol. 2005; 18: 779-790.
50. Mittman N, Khanna R, Rani S, Chattopadhyay J, Avram MM. Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: A single-center crossover study. Kidney Int. 2006; 70 (Suppl): S64-S67.
51. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 2007; 72: 709-715.
52. Moe SM. Treatment of chronic kidney disease-mineral bone disorder and vascular complications. Ther Apher Dial. 2006; 10 (Suppl 1): S2-S15.
53. Monier-Faugere MC, Mawad H, Malluche HH. Opposite effects of calcitriol and paricalcitol on the parathyroid hormone-(1-84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with Stage 5 chronic kidney disease. Clin J Am Soc Nephrol. 2007; 2: 1255-1260.
54. 3 in the long-term treatment of renal osteodystrophy. Proc Eur Dial Transplant Assoc. 1980; 17: 543-547.
55. Nakane M, Fey TA, Dixon DB, Ma J, Brune ME, Li YC, Wu-Wong JR. Differential effects of vitamin D analogs on bone formation and resorption. J Steroid Biochem Mol Biol. 2006; 98: 72-77.
56. Nakane M, Ma J, Rose AE, Osinski MA, Wu- Wong JR. Differential effects of vitamin D analogs on calcium transport. J Steroid Biochem Mol Biol. 2007a; 103: 84-89.
57. Nakane M, Ma J, Ruan X, Kroeger PE, Wu-Wong R. Mechanistic analysis of VDR-mediated renin suppression. Nephron Physiol. 2007b; 107: 35-44.
58. Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology. 2006; 147: 5542-5548.
59. Ostrem VK, Tanaka Y, Prahl J, DeLuca HF, Ikekawa N. 24- and 26-homo-1,25-dihydroxyvitamin D3: preferential activity in inducing differentiation of human leukemia cells HL-60 in vitro. Proc Natl Acad Sci USA. 1987; 84: 2610-2614.
60. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007; 147: 840-853.
61. 3 compounds: separation of calcium and cell differentiation activities. Biochemistry. 1990; 29: 190-196.
62. Salusky IB, Goodman WG. Adynamic renal osteodystrophy: is there a problem? J Am Soc Nephrol. 2001; 12: 1978-1985.
63. Sanchez-Martinez R, Zambrano A, Castillo AI, Aranda A. Vitamin D-dependent recruitment of corepressors to vitamin D/retinoid X receptor heterodimers. Mol Cell Biol. 2008; 28: 3817-3829.
64. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis. 1995; 26: 852-860.
65. Slatopolsky E, Cozzolino M, Finch JL. Differential effects of 19-Nor-1,25-(OH)(2)D(2) and 1α-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int. 2002; 62: 1277-1284.
66. 2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia. Kidney Int. 2003; 63: 2020-2027.
67. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003; 63: 1483.
68. Suresh M, Lund R, Hruska K. Evidence for selective modulation of tissue vitamin D receptors (VDR) by vitamin D analogs. J Am Soc Nephrol. 2006; 17: SA-PO559.
69. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis. 1997; 30: 105-112.
70. Takeyama K, Masuhiro Y, Fuse H, Endoh H, Murayama A, Kitanaka S, Suzawa M, Yanagisawa J, Kato S. Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol Cell Biol. 1999; 19: 1049-1055.
71. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003; 349: 446-456.
72. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006; 70: 1858-1865.
73. Tonelli M. Vitamin D in patients with chronic kidney disease: nothing new under the sun. Ann Intern Med. 2007; 147: 880-881.
74. von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med. 1999; 106: 273-278.
75. Wolf M, Thadhani R. Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease. Semin Dial. 2005; 18: 302-306.
76. Wu- Wong JR, Noonan W, Ma J, Dixon D, Nakane M, Bolin AL, Koch KA, Postl S, Morgan SJ, Reinhart GA. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp They. 2006; 318: 90-98.
77. Wu-Wong JR, Nakane M, Ma J. Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. J Vasc Res. 2007; 44: 11-18.
78. Young EW, Albert JW, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67: 1179-1187.
79. Zhou JY, Norman AW, Lubbert M, Collins ED, Uskokovic MR, Koeffler HP. Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone mobilization. Blood. 1989; 74: 82-93.
80. 3 and parathyroid hormone. J Cell Biochem. 2003; 88: 234-237.
81. 3 in vivo and in vitro. Mol Pharmacol. 2006; 6: 1740-1747.
82. Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007; 27: 36-43.